In Brief:
The rarity of fibrolamellar hepatocellular carcinoma of these tumors, coupled with the only recent acknowledgment of genomic abnormality, has likely led to disease underrecognition and deprioritization of collaborative efforts to establish an evidence-based standard of care.
